Pierre Léonard
Corporate Officer/Principal presso Enobia Pharma, Inc.
Posizioni attive di Pierre Léonard
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/07/2009 | - |
Storia della carriera di Pierre Léonard
Formazione di Pierre Léonard
| University of Cincinnati (Ohio) | Doctorate Degree |
Statistiche
Distribuzione geografica
| Canada | 2 |
| Stati Uniti | 2 |
Posizioni
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
- Borsa valori
- Insiders
- Pierre Léonard
- Esperienza
